^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    inodiftagene vixteplasmid (BC 819)

    i
    Associations
    News

    Trials

    Company:
    ChemomAb
    Drug class:
    Gene transference
    Related drugs:
    Associations
    News

    Trials

    Apply
    Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer (NCT00826150)
    Phase 1/2
    Anchiano Therapeutics Israel Ltd.
    Completed
    Last update posted :
    06/13/2019
    Initiation :
    06/01/2009
    Primary completion :
    02/01/2012
    Completion :
    02/01/2012
    H19
    |
    inodiftagene vixteplasmid (BC 819)
    Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer (NCT00595088)
    Phase 2b
    Anchiano Therapeutics Israel Ltd.
    Completed
    Last update posted :
    04/30/2019
    Initiation :
    01/01/2008
    Primary completion :
    01/01/2013
    Completion :
    01/01/2013
    H19
    |
    inodiftagene vixteplasmid (BC 819)
    Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer (NCT00711997)
    Phase 1/2
    Anchiano Therapeutics Israel Ltd.
    Completed
    Last update posted :
    03/20/2019
    Initiation :
    08/01/2009
    Primary completion :
    10/01/2010
    Completion :
    12/01/2010
    H19
    |
    inodiftagene vixteplasmid (BC 819)